Clinical Trials Directory

Trials / Unknown

UnknownNCT03658005

Effect of Free Ticagrelor Fraction on Platelet Membrane Post MI

Population-Based Pharmacokinetic / Pharmacodynamic Modeling of the Effect of Free Ticagrelor Fraction on the Platelet Membrane in Post Myocardial Infarction Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
30 (estimated)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess: * the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor * ticagrelor and its metabolite levels by LC-MS/MS

Detailed description

Ticagrelor is an anti-platelet agent of the cyclopentyltriazolopyrimidine class. It is administered by the oral route, rapidly absorbed (2-3 hours), and has a bio-availability estimated at around 36%. Contrary to other P2Y12 inhibitors, ticagrelor is not a pro-drug and does not need to be metabolized to exert is pharmacodynamic effect. It had been previously showed that stimulation of platelets by ADP or inhibitors of platelets by ticagrelor modified the organisation of the platelet membrane, with a re-distribution of cholesterol and P2Y12 receptors towards the lipid rafts. This suggests that lipid membranes and cholesterol may play an important role in the anti-platelet activity of ticagrelor. In this context, the aim of the study is to assess: * the population pharmacokinetics of unbound ticagrelor and its metabolite in acute coronary syndrome patients treated by ticagrelor * ticagrelor and its metabolite levels by LC-MS/MS.

Conditions

Interventions

TypeNameDescription
OTHERBlood sample3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and \>6h, between two doses of ticagrelor (taken at 0 and 12 hours).

Timeline

Start date
2019-04-09
Primary completion
2022-04-09
Completion
2022-04-09
First posted
2018-09-05
Last updated
2021-02-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03658005. Inclusion in this directory is not an endorsement.